instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
What was the dosage of drug 'FILGRASTIM'? | Filgrastim associations with CAR T-cell therapy.
Little is known about the benefits and risks of myeloid growth factor administration after chimeric antigen receptor (CAR) T-cell therapy for diffuse large B-cell lymphoma (DLBCL). We present a retrospective analysis among 22 relapsed/refractory DLBCL patients who receiv... | 5 MICROGRAM/KILOGRAM, QD | DrugDosageText | CC BY-NC | 33091961 | 18,449,659 | 2021-03-01 |
What was the dosage of drug 'FLUDARABINE PHOSPHATE'? | Filgrastim associations with CAR T-cell therapy.
Little is known about the benefits and risks of myeloid growth factor administration after chimeric antigen receptor (CAR) T-cell therapy for diffuse large B-cell lymphoma (DLBCL). We present a retrospective analysis among 22 relapsed/refractory DLBCL patients who receiv... | 30 MILLIGRAM/SQ. METER, QD | DrugDosageText | CC BY-NC | 33091961 | 18,449,659 | 2021-03-01 |
What was the dosage of drug 'TOCILIZUMAB'? | Filgrastim associations with CAR T-cell therapy.
Little is known about the benefits and risks of myeloid growth factor administration after chimeric antigen receptor (CAR) T-cell therapy for diffuse large B-cell lymphoma (DLBCL). We present a retrospective analysis among 22 relapsed/refractory DLBCL patients who receiv... | 8 MILLIGRAM/KILOGRAM | DrugDosageText | CC BY-NC | 33091961 | 18,449,659 | 2021-03-01 |
What was the outcome of reaction 'Diffuse large B-cell lymphoma'? | Filgrastim associations with CAR T-cell therapy.
Little is known about the benefits and risks of myeloid growth factor administration after chimeric antigen receptor (CAR) T-cell therapy for diffuse large B-cell lymphoma (DLBCL). We present a retrospective analysis among 22 relapsed/refractory DLBCL patients who receiv... | Fatal | ReactionOutcome | CC BY-NC | 33091961 | 18,449,659 | 2021-03-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Adverse event'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Akathisia'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anxiety'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blood glucose increased'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blood insulin increased'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blood prolactin increased'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Constipation'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dizziness'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dystonia'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Electrocardiogram QT prolonged'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Headache'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'High density lipoprotein decreased'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Insomnia'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nasopharyngitis'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Parkinsonism'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Psychotic disorder'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sedation'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Somnolence'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Suicidal ideation'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tremor'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vomiting'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Weight decreased'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Weight increased'. | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | RISPERIDONE | DrugsGivenReaction | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
What was the dosage of drug 'RISPERIDONE'? | Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.
BACKGROUND
A post hoc analysis of a double-blind (DB) active control trial and an open-label extension (OLE) study was conducted to evaluate the long-term e... | 2-6 MG/DAY | DrugDosageText | CC BY-NC | 33098548 | 18,475,556 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anti factor VIII antibody positive'. | Long-Term Antithrombotic Treatments Prescribed for Cardiovascular Diseases in Patients with Hemophilia: Results from the French Registry.
Cardiovascular diseases (CVDs) are a major issue in aging patients with hemophilia (PWHs). Antithrombotic agents are widely used in the general population for CVD treatment, but this... | ANTIHEMOPHILIC FACTOR HUMAN | DrugsGivenReaction | CC BY-NC-ND | 33099283 | 19,148,168 | 2021-03 |
What was the dosage of drug 'GEMCITABINE HYDROCHLORIDE'? | Capillary leak syndrome induced by neoadjuvant cisplatin and gemcitabine in a patient with bladder cancer.
Capillary leak syndrome (CLS) is a rare disorder associated with an increased capillar permeability due to an endothelial damage, causing leakage of plasma and proteins into the interstitial compartment. CLS is ch... | UNK, CYCLIC (1000 MG/MQ Q21 FOR FOUR CYCLES) | DrugDosageText | CC BY-NC-ND | 33101987 | 18,533,173 | 2021-01 |
What was the dosage of drug 'GEMCITABINE\GEMCITABINE HYDROCHLORIDE'? | Capillary leak syndrome induced by neoadjuvant cisplatin and gemcitabine in a patient with bladder cancer.
Capillary leak syndrome (CLS) is a rare disorder associated with an increased capillar permeability due to an endothelial damage, causing leakage of plasma and proteins into the interstitial compartment. CLS is ch... | 1000 MG/MQ 1,8 Q21 | DrugDosageText | CC BY-NC-ND | 33101987 | 18,495,096 | 2021-01 |
What was the outcome of reaction 'Capillary leak syndrome'? | Capillary leak syndrome induced by neoadjuvant cisplatin and gemcitabine in a patient with bladder cancer.
Capillary leak syndrome (CLS) is a rare disorder associated with an increased capillar permeability due to an endothelial damage, causing leakage of plasma and proteins into the interstitial compartment. CLS is ch... | Recovered | ReactionOutcome | CC BY-NC-ND | 33101987 | 18,495,096 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease recurrence'. | Two cycles of adjuvant carboplatin for clinical stage 1 testicular seminoma in New Zealand centres: A retrospective analysis of efficacy and long-term events.
Adjuvant carboplatin reduces relapse risk in clinical stage 1 (CS1) seminoma, though there is a paucity of long-term safety data.
Our objective was to report ... | CARBOPLATIN | DrugsGivenReaction | CC BY | 33103860 | 19,257,839 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pulmonary embolism'. | Two cycles of adjuvant carboplatin for clinical stage 1 testicular seminoma in New Zealand centres: A retrospective analysis of efficacy and long-term events.
Adjuvant carboplatin reduces relapse risk in clinical stage 1 (CS1) seminoma, though there is a paucity of long-term safety data.
Our objective was to report ... | BLEOMYCIN SULFATE, CISPLATIN, ETOPOSIDE | DrugsGivenReaction | CC BY | 33103860 | 19,210,455 | 2021-04 |
What was the dosage of drug 'BLEOMYCIN SULFATE'? | Two cycles of adjuvant carboplatin for clinical stage 1 testicular seminoma in New Zealand centres: A retrospective analysis of efficacy and long-term events.
Adjuvant carboplatin reduces relapse risk in clinical stage 1 (CS1) seminoma, though there is a paucity of long-term safety data.
Our objective was to report ... | UNK, CYCLIC (4 CYCLES) | DrugDosageText | CC BY | 33103860 | 19,210,455 | 2021-04 |
What was the dosage of drug 'CARBOPLATIN'? | Two cycles of adjuvant carboplatin for clinical stage 1 testicular seminoma in New Zealand centres: A retrospective analysis of efficacy and long-term events.
Adjuvant carboplatin reduces relapse risk in clinical stage 1 (CS1) seminoma, though there is a paucity of long-term safety data.
Our objective was to report ... | TWO CYCLES AUC7 | DrugDosageText | CC BY | 33103860 | 19,257,839 | 2021-04 |
What was the dosage of drug 'CISPLATIN'? | Two cycles of adjuvant carboplatin for clinical stage 1 testicular seminoma in New Zealand centres: A retrospective analysis of efficacy and long-term events.
Adjuvant carboplatin reduces relapse risk in clinical stage 1 (CS1) seminoma, though there is a paucity of long-term safety data.
Our objective was to report ... | UNK, CYCLIC (4 CYCLES) | DrugDosageText | CC BY | 33103860 | 19,210,455 | 2021-04 |
What was the dosage of drug 'ETOPOSIDE'? | Two cycles of adjuvant carboplatin for clinical stage 1 testicular seminoma in New Zealand centres: A retrospective analysis of efficacy and long-term events.
Adjuvant carboplatin reduces relapse risk in clinical stage 1 (CS1) seminoma, though there is a paucity of long-term safety data.
Our objective was to report ... | UNK, CYCLIC (FOUR CYCLES) | DrugDosageText | CC BY | 33103860 | 19,210,455 | 2021-04 |
What was the outcome of reaction 'Pneumonitis'? | Two cycles of adjuvant carboplatin for clinical stage 1 testicular seminoma in New Zealand centres: A retrospective analysis of efficacy and long-term events.
Adjuvant carboplatin reduces relapse risk in clinical stage 1 (CS1) seminoma, though there is a paucity of long-term safety data.
Our objective was to report ... | Fatal | ReactionOutcome | CC BY | 33103860 | 19,257,839 | 2021-04 |
What was the outcome of reaction 'Pulmonary embolism'? | Two cycles of adjuvant carboplatin for clinical stage 1 testicular seminoma in New Zealand centres: A retrospective analysis of efficacy and long-term events.
Adjuvant carboplatin reduces relapse risk in clinical stage 1 (CS1) seminoma, though there is a paucity of long-term safety data.
Our objective was to report ... | Fatal | ReactionOutcome | CC BY | 33103860 | 19,210,455 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Borderline serous tumour of ovary'. | A serous borderline ovarian tumour in a transgender male adolescent.
Here we present a transgender male adolescent with an androgen receptor-positive serous borderline ovarian tumour in the setting of testosterone treatment for medical gender transition. To our knowledge, this is the second report of borderline tumour ... | FLUOXETINE HYDROCHLORIDE, NORETHINDRONE ACETATE, TESTOSTERONE | DrugsGivenReaction | CC BY | 33106582 | 18,557,557 | 2021-02 |
What was the administration route of drug 'TESTOSTERONE CYPIONATE'? | A serous borderline ovarian tumour in a transgender male adolescent.
Here we present a transgender male adolescent with an androgen receptor-positive serous borderline ovarian tumour in the setting of testosterone treatment for medical gender transition. To our knowledge, this is the second report of borderline tumour ... | Subcutaneous | DrugAdministrationRoute | CC BY | 33106582 | 18,563,428 | 2021-02 |
What was the administration route of drug 'TESTOSTERONE'? | A serous borderline ovarian tumour in a transgender male adolescent.
Here we present a transgender male adolescent with an androgen receptor-positive serous borderline ovarian tumour in the setting of testosterone treatment for medical gender transition. To our knowledge, this is the second report of borderline tumour ... | Subcutaneous | DrugAdministrationRoute | CC BY | 33106582 | 18,557,557 | 2021-02 |
What was the dosage of drug 'FLUOXETINE HYDROCHLORIDE'? | A serous borderline ovarian tumour in a transgender male adolescent.
Here we present a transgender male adolescent with an androgen receptor-positive serous borderline ovarian tumour in the setting of testosterone treatment for medical gender transition. To our knowledge, this is the second report of borderline tumour ... | UNKNOWN | DrugDosageText | CC BY | 33106582 | 18,563,428 | 2021-02 |
What was the dosage of drug 'TESTOSTERONE CYPIONATE'? | A serous borderline ovarian tumour in a transgender male adolescent.
Here we present a transgender male adolescent with an androgen receptor-positive serous borderline ovarian tumour in the setting of testosterone treatment for medical gender transition. To our knowledge, this is the second report of borderline tumour ... | UNKNOWN | DrugDosageText | CC BY | 33106582 | 18,563,428 | 2021-02 |
What was the outcome of reaction 'Borderline ovarian tumour'? | A serous borderline ovarian tumour in a transgender male adolescent.
Here we present a transgender male adolescent with an androgen receptor-positive serous borderline ovarian tumour in the setting of testosterone treatment for medical gender transition. To our knowledge, this is the second report of borderline tumour ... | Recovered | ReactionOutcome | CC BY | 33106582 | 18,563,428 | 2021-02 |
What was the outcome of reaction 'Borderline serous tumour of ovary'? | A serous borderline ovarian tumour in a transgender male adolescent.
Here we present a transgender male adolescent with an androgen receptor-positive serous borderline ovarian tumour in the setting of testosterone treatment for medical gender transition. To our knowledge, this is the second report of borderline tumour ... | Recovering | ReactionOutcome | CC BY | 33106582 | 18,557,557 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute myocardial infarction'. | Paraneoplastic Syndrome and SARS-CoV-2-Incremental Effect of 2 Thrombogenic Conditions?
We present the case of a patient with a nonbacterial thrombotic aortic valve endocarditis experiencing severe thromboembolic complications and an acute right internal carotid artery occlusion in the context of a paraneoplastic syndr... | RIVAROXABAN | DrugsGivenReaction | CC BY-NC-ND | 33106785 | 19,014,282 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Paraneoplastic Syndrome and SARS-CoV-2-Incremental Effect of 2 Thrombogenic Conditions?
We present the case of a patient with a nonbacterial thrombotic aortic valve endocarditis experiencing severe thromboembolic complications and an acute right internal carotid artery occlusion in the context of a paraneoplastic syndr... | RIVAROXABAN | DrugsGivenReaction | CC BY-NC-ND | 33106785 | 19,014,282 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Endocarditis noninfective'. | Paraneoplastic Syndrome and SARS-CoV-2-Incremental Effect of 2 Thrombogenic Conditions?
We present the case of a patient with a nonbacterial thrombotic aortic valve endocarditis experiencing severe thromboembolic complications and an acute right internal carotid artery occlusion in the context of a paraneoplastic syndr... | RIVAROXABAN | DrugsGivenReaction | CC BY-NC-ND | 33106785 | 19,014,282 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'International normalised ratio increased'. | Paraneoplastic Syndrome and SARS-CoV-2-Incremental Effect of 2 Thrombogenic Conditions?
We present the case of a patient with a nonbacterial thrombotic aortic valve endocarditis experiencing severe thromboembolic complications and an acute right internal carotid artery occlusion in the context of a paraneoplastic syndr... | RIVAROXABAN | DrugsGivenReaction | CC BY-NC-ND | 33106785 | 19,014,282 | 2021-02 |
What was the administration route of drug 'RIVAROXABAN'? | Paraneoplastic Syndrome and SARS-CoV-2-Incremental Effect of 2 Thrombogenic Conditions?
We present the case of a patient with a nonbacterial thrombotic aortic valve endocarditis experiencing severe thromboembolic complications and an acute right internal carotid artery occlusion in the context of a paraneoplastic syndr... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33106785 | 19,014,282 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fatigue'. | Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibit... | LEVOTHYROXINE SODIUM, METFORMIN HYDROCHLORIDE, ONDANSETRON, TEMOZOLOMIDE, TESTOSTERONE | DrugsGivenReaction | CC BY | 33112279 | 18,702,402 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Malignant neoplasm progression'. | Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibit... | LEVOTHYROXINE SODIUM, METFORMIN HYDROCHLORIDE, ONDANSETRON, TEMOZOLOMIDE, TESTOSTERONE | DrugsGivenReaction | CC BY | 33112279 | 18,702,402 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibit... | LEVOTHYROXINE SODIUM, METFORMIN HYDROCHLORIDE, ONDANSETRON, TEMOZOLOMIDE, TESTOSTERONE | DrugsGivenReaction | CC BY | 33112279 | 18,702,402 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibit... | LEVOTHYROXINE SODIUM, METFORMIN HYDROCHLORIDE, ONDANSETRON, TEMOZOLOMIDE, TESTOSTERONE | DrugsGivenReaction | CC BY | 33112279 | 18,702,402 | 2021-01 |
What is the weight of the patient? | Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibit... | 115.6 kg. | Weight | CC BY | 33112279 | 18,702,402 | 2021-01 |
What was the administration route of drug 'LEVOTHYROXINE SODIUM'? | Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibit... | Oral | DrugAdministrationRoute | CC BY | 33112279 | 18,702,402 | 2021-01 |
What was the administration route of drug 'METFORMIN HYDROCHLORIDE'? | Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibit... | Oral | DrugAdministrationRoute | CC BY | 33112279 | 18,702,402 | 2021-01 |
What was the administration route of drug 'ONDANSETRON'? | Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibit... | Oral | DrugAdministrationRoute | CC BY | 33112279 | 18,702,402 | 2021-01 |
What was the administration route of drug 'TEMOZOLOMIDE'? | Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibit... | Oral | DrugAdministrationRoute | CC BY | 33112279 | 18,702,402 | 2021-01 |
What was the administration route of drug 'TESTOSTERONE'? | Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibit... | Intramuscular | DrugAdministrationRoute | CC BY | 33112279 | 18,702,402 | 2021-01 |
What was the dosage of drug 'TEMOZOLOMIDE'? | Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibit... | 150?200 MG/M2, 5 DAYS IN A 28?DAY CYCLE (EVERY 4 WEEKS) | DrugDosageText | CC BY | 33112279 | 18,702,402 | 2021-01 |
What was the outcome of reaction 'Fatigue'? | Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibit... | Not recovered | ReactionOutcome | CC BY | 33112279 | 18,702,402 | 2021-01 |
What was the outcome of reaction 'Nausea'? | Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibit... | Recovered | ReactionOutcome | CC BY | 33112279 | 18,702,402 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Death'. | Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors.
Disease relapse is an important problem after allogeneic stem cell transplantations in multiple myeloma (MM). To test the hypothesis that natural killer (NK) cell alloreactivity in the setting of a ha... | BUSULFAN, CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, MYCOPHENOLATE MOFETIL, TACROLIMUS | DrugsGivenReaction | CC BY | 33112968 | 18,787,258 | 2021-01 |
What was the dosage of drug 'FLUDARABINE PHOSPHATE'? | Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors.
Disease relapse is an important problem after allogeneic stem cell transplantations in multiple myeloma (MM). To test the hypothesis that natural killer (NK) cell alloreactivity in the setting of a ha... | DAY 6 TO 2 BEFORE TRANSPLANTATION. | DrugDosageText | CC BY | 33112968 | 18,787,258 | 2021-01 |
What was the dosage of drug 'MYCOPHENOLATE MOFETIL'? | Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors.
Disease relapse is an important problem after allogeneic stem cell transplantations in multiple myeloma (MM). To test the hypothesis that natural killer (NK) cell alloreactivity in the setting of a ha... | ON DAY + 5 TO + 35 POST TRANSPLANT | DrugDosageText | CC BY | 33112968 | 18,787,258 | 2021-01 |
What was the dosage of drug 'TACROLIMUS'? | Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors.
Disease relapse is an important problem after allogeneic stem cell transplantations in multiple myeloma (MM). To test the hypothesis that natural killer (NK) cell alloreactivity in the setting of a ha... | ON DAY + 5 TO + 180 POST TRANSPLANT. | DrugDosageText | CC BY | 33112968 | 18,787,258 | 2021-01 |
What was the outcome of reaction 'Death'? | Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors.
Disease relapse is an important problem after allogeneic stem cell transplantations in multiple myeloma (MM). To test the hypothesis that natural killer (NK) cell alloreactivity in the setting of a ha... | Fatal | ReactionOutcome | CC BY | 33112968 | 18,787,258 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Atonic seizures'. | Lennox-Gastaut Syndrome: Perspective of a Parent and a Physician.
This article is co-authored by a parent of a 32-year-old male patient with Lennox-Gastaut syndrome (LGS) and his epileptologist. It discusses the parent's experience of having a child with LGS from diagnosis through living day-to-day with the disease and... | CLOBAZAM, LAMOTRIGINE, LEVETIRACETAM, PRIMIDONE | DrugsGivenReaction | CC BY-NC | 33113098 | 19,651,858 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Epilepsy'. | Lennox-Gastaut Syndrome: Perspective of a Parent and a Physician.
This article is co-authored by a parent of a 32-year-old male patient with Lennox-Gastaut syndrome (LGS) and his epileptologist. It discusses the parent's experience of having a child with LGS from diagnosis through living day-to-day with the disease and... | RUFINAMIDE | DrugsGivenReaction | CC BY-NC | 33113098 | 19,373,247 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Generalised tonic-clonic seizure'. | Lennox-Gastaut Syndrome: Perspective of a Parent and a Physician.
This article is co-authored by a parent of a 32-year-old male patient with Lennox-Gastaut syndrome (LGS) and his epileptologist. It discusses the parent's experience of having a child with LGS from diagnosis through living day-to-day with the disease and... | CLOBAZAM, LAMOTRIGINE, LEVETIRACETAM, PRIMIDONE | DrugsGivenReaction | CC BY-NC | 33113098 | 19,651,858 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Multiple-drug resistance'. | Lennox-Gastaut Syndrome: Perspective of a Parent and a Physician.
This article is co-authored by a parent of a 32-year-old male patient with Lennox-Gastaut syndrome (LGS) and his epileptologist. It discusses the parent's experience of having a child with LGS from diagnosis through living day-to-day with the disease and... | CLOBAZAM, LAMOTRIGINE, LEVETIRACETAM, PRIMIDONE | DrugsGivenReaction | CC BY-NC | 33113098 | 19,651,858 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Petit mal epilepsy'. | Lennox-Gastaut Syndrome: Perspective of a Parent and a Physician.
This article is co-authored by a parent of a 32-year-old male patient with Lennox-Gastaut syndrome (LGS) and his epileptologist. It discusses the parent's experience of having a child with LGS from diagnosis through living day-to-day with the disease and... | CLOBAZAM, LAMOTRIGINE, LEVETIRACETAM, PRIMIDONE | DrugsGivenReaction | CC BY-NC | 33113098 | 19,651,858 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use issue'. | Lennox-Gastaut Syndrome: Perspective of a Parent and a Physician.
This article is co-authored by a parent of a 32-year-old male patient with Lennox-Gastaut syndrome (LGS) and his epileptologist. It discusses the parent's experience of having a child with LGS from diagnosis through living day-to-day with the disease and... | CLOBAZAM, LAMOTRIGINE, LEVETIRACETAM, PRIMIDONE | DrugsGivenReaction | CC BY-NC | 33113098 | 19,651,858 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sedation'. | Lennox-Gastaut Syndrome: Perspective of a Parent and a Physician.
This article is co-authored by a parent of a 32-year-old male patient with Lennox-Gastaut syndrome (LGS) and his epileptologist. It discusses the parent's experience of having a child with LGS from diagnosis through living day-to-day with the disease and... | CLOBAZAM, LAMOTRIGINE, LEVETIRACETAM, PRIMIDONE, RUFINAMIDE | DrugsGivenReaction | CC BY-NC | 33113098 | 19,783,468 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tonic convulsion'. | Lennox-Gastaut Syndrome: Perspective of a Parent and a Physician.
This article is co-authored by a parent of a 32-year-old male patient with Lennox-Gastaut syndrome (LGS) and his epileptologist. It discusses the parent's experience of having a child with LGS from diagnosis through living day-to-day with the disease and... | CLOBAZAM, LAMOTRIGINE, LEVETIRACETAM, PRIMIDONE | DrugsGivenReaction | CC BY-NC | 33113098 | 19,651,858 | 2021-06 |
What was the administration route of drug 'RUFINAMIDE'? | Lennox-Gastaut Syndrome: Perspective of a Parent and a Physician.
This article is co-authored by a parent of a 32-year-old male patient with Lennox-Gastaut syndrome (LGS) and his epileptologist. It discusses the parent's experience of having a child with LGS from diagnosis through living day-to-day with the disease and... | Oral | DrugAdministrationRoute | CC BY-NC | 33113098 | 19,373,247 | 2021-06 |
What was the outcome of reaction 'Atonic seizures'? | Lennox-Gastaut Syndrome: Perspective of a Parent and a Physician.
This article is co-authored by a parent of a 32-year-old male patient with Lennox-Gastaut syndrome (LGS) and his epileptologist. It discusses the parent's experience of having a child with LGS from diagnosis through living day-to-day with the disease and... | Recovering | ReactionOutcome | CC BY-NC | 33113098 | 19,651,858 | 2021-06 |
What was the outcome of reaction 'Generalised tonic-clonic seizure'? | Lennox-Gastaut Syndrome: Perspective of a Parent and a Physician.
This article is co-authored by a parent of a 32-year-old male patient with Lennox-Gastaut syndrome (LGS) and his epileptologist. It discusses the parent's experience of having a child with LGS from diagnosis through living day-to-day with the disease and... | Recovering | ReactionOutcome | CC BY-NC | 33113098 | 19,651,858 | 2021-06 |
What was the outcome of reaction 'Petit mal epilepsy'? | Lennox-Gastaut Syndrome: Perspective of a Parent and a Physician.
This article is co-authored by a parent of a 32-year-old male patient with Lennox-Gastaut syndrome (LGS) and his epileptologist. It discusses the parent's experience of having a child with LGS from diagnosis through living day-to-day with the disease and... | Recovering | ReactionOutcome | CC BY-NC | 33113098 | 19,651,858 | 2021-06 |
What was the outcome of reaction 'Tonic convulsion'? | Lennox-Gastaut Syndrome: Perspective of a Parent and a Physician.
This article is co-authored by a parent of a 32-year-old male patient with Lennox-Gastaut syndrome (LGS) and his epileptologist. It discusses the parent's experience of having a child with LGS from diagnosis through living day-to-day with the disease and... | Recovering | ReactionOutcome | CC BY-NC | 33113098 | 19,651,858 | 2021-06 |
What was the administration route of drug 'PERAMIVIR'? | Recurrence of Acute Lymphoblastic Leukemia with Bone Marrow Necrosis: A Case Report and Review of the Literature on the MRI Features of Bone Marrow Necrosis.
Bone marrow necrosis (BMN) is a rare but important complication of hematological malignancies. We report the case of a 52-year-old male patient with a recurrence ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33116012 | 20,408,999 | 2021-04-01 |
What was the administration route of drug 'VORICONAZOLE'? | Recurrence of Acute Lymphoblastic Leukemia with Bone Marrow Necrosis: A Case Report and Review of the Literature on the MRI Features of Bone Marrow Necrosis.
Bone marrow necrosis (BMN) is a rare but important complication of hematological malignancies. We report the case of a 52-year-old male patient with a recurrence ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33116012 | 20,408,999 | 2021-04-01 |
What was the dosage of drug 'INOTUZUMAB OZOGAMICIN'? | Recurrence of Acute Lymphoblastic Leukemia with Bone Marrow Necrosis: A Case Report and Review of the Literature on the MRI Features of Bone Marrow Necrosis.
Bone marrow necrosis (BMN) is a rare but important complication of hematological malignancies. We report the case of a 52-year-old male patient with a recurrence ... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY-NC-ND | 33116012 | 20,073,058 | 2021-04-01 |
What was the dosage of drug 'MICAFUNGIN'? | Recurrence of Acute Lymphoblastic Leukemia with Bone Marrow Necrosis: A Case Report and Review of the Literature on the MRI Features of Bone Marrow Necrosis.
Bone marrow necrosis (BMN) is a rare but important complication of hematological malignancies. We report the case of a 52-year-old male patient with a recurrence ... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY-NC-ND | 33116012 | 20,073,058 | 2021-04-01 |
What was the dosage of drug 'PERAMIVIR'? | Recurrence of Acute Lymphoblastic Leukemia with Bone Marrow Necrosis: A Case Report and Review of the Literature on the MRI Features of Bone Marrow Necrosis.
Bone marrow necrosis (BMN) is a rare but important complication of hematological malignancies. We report the case of a 52-year-old male patient with a recurrence ... | 300 MG, QD | DrugDosageText | CC BY-NC-ND | 33116012 | 20,408,999 | 2021-04-01 |
What was the dosage of drug 'VORICONAZOLE'? | Recurrence of Acute Lymphoblastic Leukemia with Bone Marrow Necrosis: A Case Report and Review of the Literature on the MRI Features of Bone Marrow Necrosis.
Bone marrow necrosis (BMN) is a rare but important complication of hematological malignancies. We report the case of a 52-year-old male patient with a recurrence ... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY-NC-ND | 33116012 | 20,073,058 | 2021-04-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastric polyps'. | Gastric Hyperplastic Polyps after Argon Plasma Coagulation for Gastric Antral Vascular Ectasia in Patients with Liver Cirrhosis: A Case Suggesting the "Gastrin Link Theory".
We herein report a case of gastric hyperplastic polyps after argon plasma coagulation (APC) for gastric antral vascular ectasia (GAVE) in the antr... | ESOMEPRAZOLE | DrugsGivenReaction | CC BY-NC-ND | 33116013 | 20,089,064 | 2021-04-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypergastrinaemia'. | Gastric Hyperplastic Polyps after Argon Plasma Coagulation for Gastric Antral Vascular Ectasia in Patients with Liver Cirrhosis: A Case Suggesting the "Gastrin Link Theory".
We herein report a case of gastric hyperplastic polyps after argon plasma coagulation (APC) for gastric antral vascular ectasia (GAVE) in the antr... | ESOMEPRAZOLE | DrugsGivenReaction | CC BY-NC-ND | 33116013 | 20,089,064 | 2021-04-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Iron deficiency anaemia'. | Gastric Hyperplastic Polyps after Argon Plasma Coagulation for Gastric Antral Vascular Ectasia in Patients with Liver Cirrhosis: A Case Suggesting the "Gastrin Link Theory".
We herein report a case of gastric hyperplastic polyps after argon plasma coagulation (APC) for gastric antral vascular ectasia (GAVE) in the antr... | ESOMEPRAZOLE | DrugsGivenReaction | CC BY-NC-ND | 33116013 | 20,089,064 | 2021-04-01 |
What was the outcome of reaction 'Gastric polyps'? | Gastric Hyperplastic Polyps after Argon Plasma Coagulation for Gastric Antral Vascular Ectasia in Patients with Liver Cirrhosis: A Case Suggesting the "Gastrin Link Theory".
We herein report a case of gastric hyperplastic polyps after argon plasma coagulation (APC) for gastric antral vascular ectasia (GAVE) in the antr... | Recovered | ReactionOutcome | CC BY-NC-ND | 33116013 | 20,089,064 | 2021-04-01 |
What was the outcome of reaction 'Hypergastrinaemia'? | Gastric Hyperplastic Polyps after Argon Plasma Coagulation for Gastric Antral Vascular Ectasia in Patients with Liver Cirrhosis: A Case Suggesting the "Gastrin Link Theory".
We herein report a case of gastric hyperplastic polyps after argon plasma coagulation (APC) for gastric antral vascular ectasia (GAVE) in the antr... | Recovering | ReactionOutcome | CC BY-NC-ND | 33116013 | 20,089,064 | 2021-04-01 |
What was the outcome of reaction 'Iron deficiency anaemia'? | Gastric Hyperplastic Polyps after Argon Plasma Coagulation for Gastric Antral Vascular Ectasia in Patients with Liver Cirrhosis: A Case Suggesting the "Gastrin Link Theory".
We herein report a case of gastric hyperplastic polyps after argon plasma coagulation (APC) for gastric antral vascular ectasia (GAVE) in the antr... | Recovered | ReactionOutcome | CC BY-NC-ND | 33116013 | 20,089,064 | 2021-04-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Generalized herpes zoster and cutaneous metastasis during chemotherapy for non-small cell lung cancer: A case report.
Although herpes zoster is known to occur in some patients with lung cancer, generalized (disseminated) herpes zoster is an uncommon form whereby hematogenous dissemination of the virus occurs and leads ... | DOCETAXEL | DrugsGivenReaction | CC BY | 33118287 | 18,485,283 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lung squamous cell carcinoma metastatic'. | Generalized herpes zoster and cutaneous metastasis during chemotherapy for non-small cell lung cancer: A case report.
Although herpes zoster is known to occur in some patients with lung cancer, generalized (disseminated) herpes zoster is an uncommon form whereby hematogenous dissemination of the virus occurs and leads ... | ACYCLOVIR, CARBOPLATIN, GIMERACIL\OTERACIL\TEGAFUR, RADIATION THERAPY | DrugsGivenReaction | CC BY | 33118287 | 18,760,944 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Malignant neoplasm progression'. | Generalized herpes zoster and cutaneous metastasis during chemotherapy for non-small cell lung cancer: A case report.
Although herpes zoster is known to occur in some patients with lung cancer, generalized (disseminated) herpes zoster is an uncommon form whereby hematogenous dissemination of the virus occurs and leads ... | CARBOPLATIN, DOCETAXEL, DURVALUMAB, GIMERACIL\OTERACIL\TEGAFUR, PACLITAXEL | DrugsGivenReaction | CC BY | 33118287 | 18,516,222 | 2021-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to central nervous system'. | Generalized herpes zoster and cutaneous metastasis during chemotherapy for non-small cell lung cancer: A case report.
Although herpes zoster is known to occur in some patients with lung cancer, generalized (disseminated) herpes zoster is an uncommon form whereby hematogenous dissemination of the virus occurs and leads ... | CARBOPLATIN, DOCETAXEL, DURVALUMAB, GIMERACIL\OTERACIL\TEGAFUR, PACLITAXEL | DrugsGivenReaction | CC BY | 33118287 | 18,516,222 | 2021-01 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.